Comment: EBCC 2024 highlights

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype

EAU 2024: Bladder cancer latest

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer

Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus